Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

Biotech Opyl (ASX:OPL) has entered a joint venture (JV) with US and London-based X Firm to market and  distribute its ...

Essex Bio-Technology ( (HK:1061) ) has provided an announcement.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...